COVID-19 vaccine effectiveness
(Randomized evidence)
Search studies
| Trial | Type | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Intervention 1 | Intervention 2 | |||||||
|
NCT04510207, ChiCTR2000034780 Sinopharm-Wuhan Al Kaabi N, JAMA, 2021 Full text Commentary Commentary |
Inactivated virus |
WIBP-CorV |
Adjuvant |
RCTPhase 3 | Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain | N= 40411 |
Some concerns Details |
|
|
ChiCTR2000031809 Sinopharm-Wuhan Guo W, EClinicalMedicine, 2021 Full text Commentary |
Inactivated virus |
WIBP-CorV 5 mcg D0/21 |
Adjuvant |
RCTPhase 1-2 | Healthy adults with no history of COVID-19 at 5 centers in China. | N= 1120 |
Some concerns Details |
|
|
ChiCTR2000031809 Sinopharm-Wuhan Xia S, JAMA, 2020 Full text Commentary |
Inactivated virus |
WIBP-CorV 5mcg-D0/28/56 |
Placebo |
RCTPhase 1 | Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test | N= NR |
Low Details |
|